AMAG Pharmaceuticals Inc.
http://www.amagpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AMAG Pharmaceuticals Inc.
Recursion’s REC-994 Passes Phase II, But Needs To Find Right Dosage, Endpoints For Next Study
The study, in cerebral cavernous malformation (CCM), hit the safety primary endpoint and showed signals in efficacy, but analysts pointed out that the bar for success in the disease remains unclear.
Finance Watch: Zenas, Bicara, MBX Aim To Raise $100m Or More In Future IPOs
Fifteen biopharma firms have launched IPOs in the US this year, but three more have joined the queue. Also, Galderma sold CHF500m ($590.7m) in bonds to pay down debt, Noetik raised a $40m series A round and ImCheck collected €20.18m ($22.4m) from the French government.
UCB Divests Products, Manufacturing Site In China To CBC, Mubadala
Deal Snapshot: The Belgian company follows a tradition of Western pharma companies relying on local expertise to market their products in China.
Deal Watch: Revance To Go Private In Crown Laboratories Buyout
Plus deals involving AstraZeneca/Conduit, Recursion/Exscientia, G1/Pharmacosmos, Sanofi/Vir, Passage Bio/GEMMA and Lupin/Evofem. Also including deals in brief.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Advanced Magnetics, Inc.
- Cord Blood Registry (CBR)
- Ethex Corporation
- K-V Pharmaceutical Company (KV Pharmaceutical)
- Lumara Health Inc.
- Perosphere Inc.
- Perosphere Pharmaceuticals
- Ther-Rx Corporation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice